Two Binding Geometries for Risperidone in Dopamine D3 Receptors: Insights on the Fast-Off Mechanism through Docking, Quantum Biochemistry, and Molecular Dynamics Simulations.

No abstract is available for this paper.

• Publication year

  2016

• Venue

  ACS Chemical Neuroscience

• Publication date

  2016-08-05

• Fields of study

  Medicine, Chemistry

• Identifiers
  DOI 10.1021/ACSCHEMNEURO.6B00074PMID 27434874
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• The Global Burden of Mental, Neurological and Substance Use Disorders: An Analysis from the Global Burden of Disease Study 2010

  2015cited by this paper
• Antipsychotic haloperidol binding to the human dopamine D3 receptor: beyond docking through QM/MM refinement toward the design of improved schizophrenia medicines.

  2014cited by this paper
• Global burden of disease attributable to mental and substance use disorders: findings from the Global Burden of Disease Study 2010.

  2013cited by this paper
• Current approaches to treatments for schizophrenia spectrum disorders, part I: an overview and medical treatments

  2013cited by this paper
• Dopamine D3 receptor antagonists: a patent review (2007 – 2012)

  2013cited by this paper
• The potential role of dopamine D₃ receptor neurotransmission in cognition.

  2013cited by this paper
• Clozapine, atypical antipsychotics, and the benefits of fast-off D2 dopamine receptor antagonism

  2012cited by this paper
• Efficacy of risperidone in managing maladaptive behaviors for children with autistic spectrum disorder: a meta-analysis.

  2012cited by this paper
• Implementation of empirical dispersion corrections to density functional theory for periodic systems

  2012cited by this paper
• Homology Modeling of Dopamine D2 and D3 Receptors: Molecular Dynamics Refinement and Docking Evaluation

  2012cited by this paper
• Explaining statin inhibition effectiveness of HMG-CoA reductase by quantum biochemistry computations.

  2012cited by this paper
• Inactivation of ovine cyclooxygenase-1 by bromoaspirin and aspirin: a quantum chemistry description.

  2012cited by this paper
• Fragmentation methods: a route to accurate calculations on large systems.

  2012cited by this paper
• High-affinity and selective dopamine D₃ receptor full agonists.

  2012cited by this paper
• Selectivity and activation of dopamine D3R from molecular dynamics

  2012cited by this paper
• Pharmacokinetics and central nervous system effects of the novel dopamine D2 receptor antagonist JNJ-37822681

  2012cited by this paper
• Ligand Discovery from a Dopamine D3 Receptor Homology Model and Crystal Structure

  2011cited by this paper
• Frozen out: molecular modeling in the age of cryocrystallography

  2011cited by this paper
• Recent advances in the search for D3- and D4-selective drugs: probes, models and candidates.

  2011cited by this paper
• Quantum Mechanics/Molecular Mechanics Strategies for Docking Pose Refinement: Distinguishing between Binders and Decoys in Cytochrome c Peroxidase

  2011cited by this paper
• Interaction of novel hybrid compounds with the D3 dopamine receptor: Site-directed mutagenesis and homology modeling studies.

  2011cited by this paper
• Quantum mechanical methods for drug design.

  2010cited by this paper
• Structure of the Human Dopamine D3 Receptor in Complex with a D2/D3 Selective Antagonist

  2010cited by this paper
• Matrix metalloproteinase 2 inhibition: combined quantum mechanics and molecular mechanics studies of the inhibition mechanism of (4-phenoxyphenylsulfonyl)methylthiirane and its oxirane analogue.

  2009cited by this paper
• AutoDock4 and AutoDockTools4: Automated docking with selective receptor flexibility

  2009cited by this paper
• Quantum mechanical scoring for protein docking.

  2009cited by this paper
• Accurate molecular van der Waals interactions from ground-state electron density and free-atom reference data.

  2009cited by this paper
• Synthesis, binding affinity, and molecular docking analysis of new benzofuranone derivatives as potential antipsychotics.

  2008cited by this paper
• Empirical entropic contributions in computational docking: Evaluation in APS reductase complexes

  2008cited by this paper
• Exploring the Limit of Accuracy of the Global Hybrid Meta Density Functional for Main-Group Thermochemistry, Kinetics, and Noncovalent Interactions.

  2008cited by this paper
• Critical thoughts on computing atom condensed Fukui functions.

  2007cited by this paper
• Critical analysis and extension of the Hirshfeld atoms in molecules.

  2007cited by this paper
• The role of quantum mechanics in structure-based drug design.

  2007cited by this paper
• Multistructure 3D-QSAR studies on a series of conformationally constrained butyrophenones docked into a new homology model of the 5-HT2A receptor.

  2007cited by this paper
• Implicit flexibility in protein docking: Cross‐docking and local refinement

  2007cited by this paper
• A semiempirical free energy force field with charge‐based desolvation

  2007cited by this paper
• Crystal structure of the human beta2 adrenergic G-protein-coupled receptor.

  2007cited by this paper
• Do structurally similar ligands bind in a similar fashion?

  2006cited by this paper
• Dopamine D2 and D3 receptors in human putamen, caudate nucleus, and globus pallidus

  2006cited by this paper
• Protein–ligand docking: Current status and future challenges

  2006cited by this paper
• GROMACS: Fast, flexible, and free

  2005cited by this paper
• A new method for direct calculation of total energy of protein.

  2005cited by this paper
• An efficient approach for ab initio energy calculation of biopolymers.

  2005cited by this paper
• Validation of the 53A6 GROMOS force field

  2005cited by this paper
• Atypical and typical antipsychotic drug interactions with the dopamine D2 receptor.

  2005cited by this paper
• Design, synthesis and structure-activity relationship studies of hexahydropyrazinoquinolines as a novel class of potent and selective dopamine receptor 3 (D3) ligands.

  2005cited by this paper
• What is an atom in a molecule?

  2005cited by this paper
• Pyrrolo[1,3]benzothiazepine-based serotonin and dopamine receptor antagonists. Molecular modeling, further structure-activity relationship studies, and identification of novel atypical antipsychotic agents.

  2004cited by this paper
• Pramipexole for bipolar II depression: a placebo-controlled proof of concept study.

  2004cited by this paper
• Risperidone in the Treatment of Disruptive Behavioral Symptoms in Children With Autistic and Other Pervasive Developmental Disorders

  2004cited by this paper
• Disease model: Parkinson's disease.

  2003cited by this paper
• The ups and downs of novel antiemetic drugs, part 1: substance P, 5-HT, and the neuropharmacology of vomiting.

  2003cited by this paper
• Geometry optimization with QM/MM, ONIOM, and other combined methods. I. Microiterations and constraints

  2003cited by this paper
• Pharmacological actions of a novel and selective dopamine D3 receptor antagonist, KCH-1110.

  2003cited by this paper
• Implications of protein flexibility for drug discovery

  2003cited by this paper
• Molecular recognition and docking algorithms.

  2003cited by this paper
• Gene expression patterns during enhanced periods of visual cortex plasticity.

  2002cited by this paper
• Atypical Antipsychotics: Mechanism of Action

  2002cited by this paper
• Antipsychotic drugs: importance of dopamine receptors for mechanisms of therapeutic actions and side effects.

  2001cited by this paper
• High-throughput docking for lead generation.

  2001cited by this paper
• Does fast dissociation from the dopamine d(2) receptor explain the action of atypical antipsychotics?: A new hypothesis.

  2001cited by this paper
• A Paradigm Shift in Brain Research

  2001cited by this paper
• Dopamine D3 receptor as a therapeutic target for antipsychotic and antiparkinsonian drugs.

  2001cited by this paper
• Antipsychotic agents differ in how fast they come off the dopamine D2 receptors. Implications for atypical antipsychotic action.

  2000cited by this paper
• Information theory, atoms in molecules, and molecular similarity.

  2000cited by this paper
• The Role of Serotonin in Antipsychotic Drug Action

  1999cited by this paper
• Conformationally constrained butyrophenones with mixed dopaminergic (D(2)) and serotoninergic (5-HT(2A), 5-HT(2C)) affinities: synthesis, pharmacology, 3D-QSAR, and molecular modeling of (aminoalkyl)benzo- and -thienocycloalkanones as putative atypical antipsychotics.

  1999cited by this paper
• Python: a programming language for software integration and development.

  1999cited by this paper
• Rapid release of antipsychotic drugs from dopamine D2 receptors: an explanation for low receptor occupancy and early clinical relapse upon withdrawal of clozapine or quetiapine.

  1999cited by this paper
• Dopamine receptors: from structure to function.

  1998cited by this paper
• Contributions of cysteine 114 of the human D3 dopamine receptor to ligand binding and sensitivity to external oxidizing agents

  1998cited by this paper
• Linking the Family of D2 Receptors to Neuronal Circuits in Human Brain: Insights into Schizophrenia

  1997cited by this paper
• Generalized Gradient Approximation Made Simple.

  1996cited by this paper
• Risperidone compared with new and reference antipsychotic drugs: in vitro and in vivo receptor binding

  1996cited by this paper
• Dopamine receptors and brain function.

  1996cited by this paper
• Molecular basis for the binding of 2-aminotetralins to human dopamine D2A and D3 receptors.

  1994cited by this paper
• Molecular biology of dopamine receptors.

  1992cited by this paper
• Accurate and simple analytic representation of the electron-gas correlation energy.

  1992cited by this paper
• Mutagenesis of the beta 2-adrenergic receptor: how structure elucidates function.

  1992cited by this paper
• Molecular cloning and characterization of a novel dopamine receptor (D3) as a target for neuroleptics

  1990cited by this paper
• Classification of typical and atypical antipsychotic drugs on the basis of dopamine D-1, D-2 and serotonin2 pKi values.

  1989cited by this paper
• Pharmacology of risperidone (R 64 766), a new antipsychotic with serotonin-S2 and dopamine-D2 antagonistic properties.

  1988cited by this paper
• Negative v positive schizophrenia. Definition and validation.

  1982cited by this paper
• A ternary complex model explains the agonist-specific binding properties of the adenylate cyclase-coupled beta-adrenergic receptor.

  1980cited by this paper
• Multiple receptors for dopamine

  1979cited by this paper
• Antipsychotic drug doses and neuroleptic/dopamine receptors

  1976cited by this paper

• Study of Calcitriol Interaction with the Vitamin D Receptor Using DFT and TD-DFT Calculations

  2026cites this paper
• In Silico Exploration of Hydroxytetrahydroxanthes as Promising Antipsychotic Candidates: A Molecular Docking, Molecular Simulation, DFT, and ADMET Study

  2025cites this paper
• Quantum Biochemistry Characterization of Representative Conformations of The Sex Hormone-Binding Globulin Monomer Bound to Estradiol, Dihydrotestosterone and Testosterone.

  2025cites this paper
• Integrating classical and quantum mechanics in melatonin receptors for structure-guided drug design

  2025cites this paper
• Oxazole and isoxazole-containing pharmaceuticals: targets, pharmacological activities, and their SAR studies.

  2025cites this paper
• Alzheimer’s Disease Immunotherapy and Mimetic Peptide Design for Drug Development: Mutation Screening, Molecular Dynamics, and a Quantum Biochemistry Approach Focusing on Aducanumab::Aβ2–7 Binding Affinity

  2024cites this paper
• Quantum biochemistry description of PI3Kα enzyme bound to selective inhibitors

  2023cites this paper
• Characterization of the binding interaction between atrazine and human serum albumin: Fluorescence spectroscopy, molecular dynamics and quantum biochemistry.

  2022cites this paper
• Losartan as an ACE inhibitor: a description of the mechanism of action through quantum biochemistry

  2022cites this paper
• Quantum Chemistry Simulation of Biological Molecules

  2020cites this paper
• mTOR–mLST8 interaction: hot spot identification through quantum biochemistry calculations

  2020cites this paper
• Antioxidant Potential of Psychotropic Drugs: From Clinical Evidence to In Vitro and In Vivo Assessment and toward a New Challenge for in Silico Molecular Design

  2020cites this paper
• In silico analysis of Sulpiride, synthesis, characterization and in vitro studies of its nanoparticle for the treatment of schizophrenia.

  2020cites this paper
• Classics in Chemical Neuroscience: Risperidone.

  2018cites this paper
• Outlining migrainous through dihydroergotamine–serotonin receptor interactions using quantum biochemistry

  2018cites this paper
• Explaining urokinase type plasminogen activator inhibition by amino-5-hydroxybenzimidazole and two naphthamidine-based compounds through quantum biochemistry.

  2018cites this paper
• Competitive association binding kinetic assays: a new tool to detect two different binding orientations of a ligand to its target protein under distinct conditions?

  2017influential citation
• An improved quantum biochemistry description of the glutamate–GluA2 receptor binding within an inhomogeneous dielectric function framework

  2017cites this paper